clinical trial · NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
B-cell Mediated Autoimmune DisordersAzercabtagene zapreleucel (azer-cel)
brief summary
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
started
May 6, 2025
primary completion
Dec 1, 2026
completion
Jan 1, 2029
last updated
Apr 7, 2026
official title
A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants With B-cell Mediated Autoimmune Disorders
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol